# Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer

> **NCT04641078** · PHASE2 · UNKNOWN · sponsor: **University Hospital, Ghent** · enrollment: 124 (estimated)

## Conditions studied

- Prostate Cancer
- Prostate Cancer Recurrent
- Prostate Cancer Metastatic
- Metastatic Cancer
- Oligometastasis

## Interventions

- **DRUG:** Darolutamide
- **RADIATION:** metastasis-directed treatment

## Key facts

- **NCT ID:** NCT04641078
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-12
- **Primary completion:** 2026-02-12
- **Final completion:** 2026-02-12
- **Target enrollment:** 124 (ESTIMATED)
- **Last updated:** 2024-02-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04641078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04641078, "Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT04641078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*